Pain Awareness Month - 60 % of permanent work incapacity in Europe is related to musculoskeletal pain

#PainCounts

Grünenthal is a global leader in pain management.

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.

Katrin Fleischer, Global Regulatory Strategy

Sabine Hess, Technician Cellular & Molecular Biology

Andrew Lockhart, Head Translational and Disease Understanding Unit

Grünenthal Stories

View All

Nearly 20 years of pain research funding by the European Pain Federation EFIC® and Grünenthal

For nearly 20 years, the European Pain Federation EFIC® and Grünenthal supported the projects of scientists in the field of pain through the EFIC®-Grünenthal-Grant (E-G-G). With a total value of €100,000, this biennial grant supports innovative projects for human pain research by early-career scient...

20 September 2023

Grünenthal Gives – an extra day a year to do things differently.

Many of our employees are involved in various corporate responsibility projects and initiatives that Grünenthal supports worldwide. One example is Grünenthal Gives, where employees get an extra day off yearly to dedicate time to the causes close to them.

31 August 2023

30 years of making Tramadol in Mitlödi

2023 marks the 30th anniversary of producing Tramadol in Mitlödi, Switzerland! Our team at this state-of-the-art facility has given patients around the globe a reliable supply of this vital pain treatment for three decades. Read more…

15 August 2023

Grünenthal kicks off Joint Venture with Kyowa Kirin

Completion of Joint Venture with Kyowa Kirin International

On 1 August 2023, Grünenthal announced the successful completion of the Joint Venture with Kyowa Kirin International (KKI). The Joint Venture comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig®...

02 August 2023

Creating cutting-edge research methods for the next generation of pain treatments

Millions of patients experience only limited pain relief from today’s medications1. New treatments are urgently needed – pain scientists at Grünenthal and their partners are creating innovative research methods with the potential to transform drug development processes.

13 July 2023

Strong new ESG rating puts Grünenthal in top 2% of the pharmaceuticals subindustry

The latest independent rating confirms Grünenthal’s improved approach to managing Environmental, Social and Governance (ESG) topics – and evaluates the company as the leader in its peer group, with a low ESG risk rating.

14 June 2023

Join us at CPHI 2023!

Grünenthal PRO is your Contract Manufacturing partner of choice if you require: a reliable and sustainable strategic partner; an integrated service provider from API to various packaged forms; a truly global supplier serving ~100 countries in the world; established track and trace for various countries; biopharma assembly, labeling, packaging in cold-chain; high expertise in scheduled drug production and handling; production and warehousing in Latin America; approvals by FDA, EMA, ANVISA & PMDA.

... CPHI Profile Grünenthal GmbH

A World Free of Pain, check out the Grünenthal Report 2022/23

Annual Report 2022/23 - Digital Edition

4,400 dedicated employees – more than 75 years of experience in developing innovative medicines – a fully integrated setup including R&D and five manufacturing sites.

These are some of the key figures that have helped us become the leading pain management company in Europe and Latin America.

For the latest insights into our people, our products and our ambitious plans to move closer to our vision of A World Free of Pain,

... check out the Grünenthal Report 2022/23

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to resiniferatoxin for pain associated with knee osteoarthritis (OA). The investigational, non-opioid medicine is currently in Phase III clinical development.

Knee OA affects more than 360 million people worldwide. Patients often experience severe pain, and many are impacted in their daily activities. If approved, resiniferatoxin could become a meaningful treatment option providing long-lasting pain relief and functional improvement of the affected joint.

Learn more about our asset and how it may address one of the most common and severe symptoms in knee OA

... Download PR FDA Breakthrough Therapy Designation for Grünenthal’s resiniferatoxin

Grünenthal announced that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX).

RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile.

... Grünenthal starts global clinical Phase III programme for resiniferatoxin (RTX)

Careers

Working at Grünenthal means experiencing the impact you can have on the results we achieve and the lives of the patients we serve.

Join forces.

Make an impact.

Innovate for a world free of pain.

... Visit our careers website